The Experts below are selected from a list of 144 Experts worldwide ranked by ideXlab platform

Per Eystein Lonning - One of the best experts on this subject based on the ideXlab platform.

  • Dose response evaluation use of plasma concentration confidence intervals as a tool to predict Optimal Drug Dose ratio
    Clinical Pharmacokinectics, 1993
    Co-Authors: Per Eystein Lonning
    Abstract:

    This paper suggests that pharmacokinetic data might provide a rational basis to improve Dose-response trials. Construction of plasma concentration confidence intervals may be a tool to predict Optimal Drug Dose ratios for Dose-response studies and, for some Drugs, may point to the need for plasma concentration measurement in clinical practice. An important task now is to integrate pharmacokinetic knowledge into the design of clinical trials. To facilitate this, studies on clinical pharmacokinetics should report individual plasma AUC or clearance values or give the 95% confidence intervals of the observation.

  • Dose Response Evaluation
    Clinical Pharmacokinetics, 1993
    Co-Authors: Per Eystein Lonning
    Abstract:

    This paper suggests that pharmacokinetic data might provide a rational basis to improve Dose-response trials. Construction of plasma concentration confidence intervals may be a tool to predict Optimal Drug Dose ratios for Dose-response studies and, for some Drugs, may point to the need for plasma concentration measurement in clinical practice. An important task now is to integrate pharmacokinetic knowledge into the design of clinical trials. To facilitate this, studies on clinical pharmacokinetics should report individual plasma AUC or clearance values or give the 95% confidence intervals of the observation.

Samir S Taneja - One of the best experts on this subject based on the ideXlab platform.

  • re determination of Optimal Drug Dose and light Dose index to achieve minimally invasive focal ablation of localized prostate cancer using wst11 vascular targeted photodynamic vtp therapy
    The Journal of Urology, 2014
    Co-Authors: Samir S Taneja
    Abstract:

    for this article http://dx.doi.org/10.1016/j.juro.2014.07.071 available at http://jurology.com/ Editorial Comment: This study of photodynamic therapy for focal treatment of prostate cancer reflects the findings in men treated in a phase I/II Dose escalation study of a vascular targeted photodynamic therapy using an agent, WST11, which largely remains in the vascular space. The Drug, when exposed to a specific wavelength of light, causes vascular thrombosis and tissue necrosis. In this study men with unilateral cancer on biopsy were subjected to gland hemiablation by vascular targeted photodynamic therapy. At increasing Doses of Drug, laser energy and number of laser fibers an Optimal combination of Drug Dose and light energy was defined. At this Dose confluent necrosis of the desired treatment volume was achieved in the majority of men treated. A previous version of the Drug, WST09, was associated with considerable toxicity, resulting in cessation of its clinical development. None of the previous toxicity was observed with the current Drug. A number of men in this and subsequent studies had residual cancer on biopsy, typically in untreated regions of the prostate. This finding illustrates the importance of 2 separate issues in evaluating the efficacy of focal therapy. First, the best method for candidate selection and cancer localization must be determined. This study falls short in addressing that issue. Systematic biopsy is clearly inadequate. The other concern, ie how to achieve confluent, complete zonal necrosis, is well addressed in this subset evaluation.

Irene Slavc - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing
    Clinical Pharmacokinetics, 2014
    Co-Authors: Andreas Peyrl, Robert Sauermann, Monika Chocholous, Amedeo A. Azizi, Walter Jäger, Martina Höferl, Irene Slavc
    Abstract:

    Background and Objective Assessment of the Optimal Drug Dose for intrathecal therapy in children is challenging because of the non-linear increase in cerebrospinal fluid (CSF) volume throughout childhood and potential differences in the elimination rate in children versus adults. The present study was designed to prospectively collect pharmacokinetic and safety data on age-adapted intrathecal liposomal cytarabine in children aged >3 years. Patients and Methods Sixteen patients with malignant brain tumours were included in the study. Children aged 3–10 years received liposomal cytarabine 35 mg with concomitant dexamethasone, and those aged >10 years received 50 mg. Serial CSF and plasma samples were collected before administration and 1 h, 12 h, 24 h, 1 week and 2 weeks post-dosing. CSF was analysed for free and encapsulated cytarabine, and plasma was analysed for free cytarabine. Results The average elimination half-life values in children aged 3–10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF. Although these values were lower than those previously reported, cytarabine concentrations exceeded the cytotoxic threshold of 0.1 mg/L in all patients until 1 week post-intraventricular administration. Cytarabine concentrations in plasma were negligible. In general, liposomal cytarabine was well tolerated, with relevant but manageable toxicities. Conclusion Liposomal cytarabine in Doses of 35 mg for children aged 3–10 years and 50 mg for older patients shows sufficient Drug exposure for at least 1 week and appears to be well tolerated.

  • Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing
    Clinical Pharmacokinectics, 2013
    Co-Authors: Andreas Peyrl, Robert Sauermann, Monika Chocholous, Amedeo A. Azizi, Walter Jäger, Martina Höferl, Irene Slavc
    Abstract:

    Background and Objective Assessment of the Optimal Drug Dose for intrathecal therapy in children is challenging because of the non-linear increase in cerebrospinal fluid (CSF) volume throughout childhood and potential differences in the elimination rate in children versus adults. The present study was designed to prospectively collect pharmacokinetic and safety data on age-adapted intrathecal liposomal cytarabine in children aged >3 years.

Andreas Peyrl - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing
    Clinical Pharmacokinetics, 2014
    Co-Authors: Andreas Peyrl, Robert Sauermann, Monika Chocholous, Amedeo A. Azizi, Walter Jäger, Martina Höferl, Irene Slavc
    Abstract:

    Background and Objective Assessment of the Optimal Drug Dose for intrathecal therapy in children is challenging because of the non-linear increase in cerebrospinal fluid (CSF) volume throughout childhood and potential differences in the elimination rate in children versus adults. The present study was designed to prospectively collect pharmacokinetic and safety data on age-adapted intrathecal liposomal cytarabine in children aged >3 years. Patients and Methods Sixteen patients with malignant brain tumours were included in the study. Children aged 3–10 years received liposomal cytarabine 35 mg with concomitant dexamethasone, and those aged >10 years received 50 mg. Serial CSF and plasma samples were collected before administration and 1 h, 12 h, 24 h, 1 week and 2 weeks post-dosing. CSF was analysed for free and encapsulated cytarabine, and plasma was analysed for free cytarabine. Results The average elimination half-life values in children aged 3–10 years and in those aged >10 years, treated with liposomal cytarabine 35 mg and 50 mg, respectively, were 40.9 and 43.7 h for free cytarabine and 31.5 and 36.4 h for encapsulated cytarabine in CSF. Although these values were lower than those previously reported, cytarabine concentrations exceeded the cytotoxic threshold of 0.1 mg/L in all patients until 1 week post-intraventricular administration. Cytarabine concentrations in plasma were negligible. In general, liposomal cytarabine was well tolerated, with relevant but manageable toxicities. Conclusion Liposomal cytarabine in Doses of 35 mg for children aged 3–10 years and 50 mg for older patients shows sufficient Drug exposure for at least 1 week and appears to be well tolerated.

  • Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing
    Clinical Pharmacokinectics, 2013
    Co-Authors: Andreas Peyrl, Robert Sauermann, Monika Chocholous, Amedeo A. Azizi, Walter Jäger, Martina Höferl, Irene Slavc
    Abstract:

    Background and Objective Assessment of the Optimal Drug Dose for intrathecal therapy in children is challenging because of the non-linear increase in cerebrospinal fluid (CSF) volume throughout childhood and potential differences in the elimination rate in children versus adults. The present study was designed to prospectively collect pharmacokinetic and safety data on age-adapted intrathecal liposomal cytarabine in children aged >3 years.

Haralambos Sarimveis - One of the best experts on this subject based on the ideXlab platform.

  • an integer programming approach for Optimal Drug Dose computation
    Computer Methods and Programs in Biomedicine, 2012
    Co-Authors: Pantelis Sopasakis, Haralambos Sarimveis
    Abstract:

    In this paper, we study the problem of determining the Optimal Drug administration strategy when only a finite number of different dosages are available, a lower bound is posed on the time intervals between two consecutive Doses, and Drug concentrations should not exceed the toxic concentration levels. The presence of only binary variables leads to the adoption of an integer programming (IP) scheme for the formulation and solution of the Drug Dose Optimal control problem. The proposed method is extended to account for the stochastic formulation of the Optimal control problem, so that it can be used in practical applications where large populations of patients are to be treated. A Finite Impulse Response (FIR) model derived from experimental pharmacokinetic data is employed to correlate the administered Drug Dose with the concentration-time profiles of the Drug in the compartments (organs) of the body.